Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease. | Endocr Rev | 2022 | 34791092 | PubTator, text mining | PubMed |
| The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. | Clin Cancer Res | 2022 | 34753780 | PubTator, text mining | PubMed |
| ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. | Blood | 2022 | 34727172 | PubTator, text mining | PubMed |
| Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. | Cancer Sci | 2022 | 34710947 | PubTator, text mining | PubMed |
| Revelation of Pivotal Genes Pertinent to Alzheimer's Pathogenesis: A Methodical Evaluation of 32 GEO Datasets. | J Mol Neurosci | 2022 | 34668150 | PubTator, text mining | PubMed |
| Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. | Cancer Discov | 2022 | 34551970 | PubTator, text mining | PubMed |
| Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells. | Anticancer Drugs | 2022 | 34520436 | PubTator, text mining | PubMed |
| Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast. | Am J Surg Pathol | 2022 | 34482333 | PubTator, text mining | PubMed |
| LRRK2 recruitment, activity, and function in organelles. | FEBS J | 2022 | 34196120 | PubTator, text mining | PubMed |
| Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. | J Clin Pathol | 2022 | 33875457 | PubTator, text mining | PubMed |
| Revision TKA with a distal femoral replacement is at high risk of reinfection after two-stage exchange for periprosthetic knee joint infection. | Knee Surg Sports Traumatol Arthrosc | 2022 | 33564916 | PubTator, text mining | PubMed |
| Protein Network Analysis of Whole Exome Sequencing of Severe Preeclampsia. | Front Genet | 2021 | 35719905 | PubTator, text mining | PubMed |
| Development of an RNA sequencing panel to detect gene fusions in thyroid cancer. | Genomics Inform | 2021 | 35172474 | PubTator, text mining | PubMed |
| Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma. | Front Oncol | 2021 | 35096557 | PubTator, text mining | PubMed |
| Clinical Manifestations and Pathogenesis of Acute Necrotizing Encephalopathy: The Interface Between Systemic Infection and Neurologic Injury. | Front Neurol | 2021 | 35058867 | PubTator, text mining | PubMed |
| Branched Actin Maintains Acetylated Microtubule Network in the Early Secretory Pathway. | Cells | 2021 | 35011578 | PubTator, text mining | PubMed |
Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report. | Front Oncol | 2021 | 35004270 | PubTator, text mining | PubMed |
| Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience. | Transl Lung Cancer Res | 2021 | 35004252 | PubTator, text mining | PubMed |
| Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report. | Onco Targets Ther | 2021 | 34992382 | PubTator, text mining | PubMed |
| Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. | MedComm (2020) | 2021 | 34977873 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=35